Abstract
Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Volume: 14 Issue: 1
Author(s): Sara Grammatico, Claudio Cartoni, Maria T. Petrucci, Pasquale Niscola, Marco Giovannini, Laura Scaramucci, Andrea Tendas, Adriana Costa, Marta Chisini, Gregorio A. Brunetti, Giada Mastrogiacomo, Sara Kiflom, Romina Talone, Giorgia Annechini, Ida Carmosino, Erminia Baldacci, Giacomo S. Morano and Giovanna Palumbo
Affiliation:
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Abstract: Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Export Options
About this article
Cite this article as:
Grammatico Sara, Cartoni Claudio, T. Petrucci Maria, Niscola Pasquale, Giovannini Marco, Scaramucci Laura, Tendas Andrea, Costa Adriana, Chisini Marta, A. Brunetti Gregorio, Mastrogiacomo Giada, Kiflom Sara, Talone Romina, Annechini Giorgia, Carmosino Ida, Baldacci Erminia, S. Morano Giacomo and Palumbo Giovanna, Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2016; 14 (1) . https://dx.doi.org/10.2174/1871525714666160405110833
DOI https://dx.doi.org/10.2174/1871525714666160405110833 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Pure Red Cell Aplasia Caused by Azathioprine
Cardiovascular & Hematological Disorders-Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Current Cancer Drug Targets The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Embryonic Stem Cell-Derived Hematopoietic Stem Cells: Challenges in Development, Differentiation, and Immunogenicity
Current Topics in Medicinal Chemistry Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Effects of Ascorbic Acid on Tax, NF-κB and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes
Anti-Cancer Agents in Medicinal Chemistry Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry